DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chan Hyuk | ko |
dc.contributor.author | Chung, Won-Suk | ko |
dc.date.accessioned | 2022-11-10T03:02:10Z | - |
dc.date.available | 2022-11-10T03:02:10Z | - |
dc.date.created | 2022-11-07 | - |
dc.date.created | 2022-11-07 | - |
dc.date.created | 2022-11-07 | - |
dc.date.issued | 2022-09 | - |
dc.identifier.citation | NATURE MEDICINE, v.28, no.9, pp.1765 - 1766 | - |
dc.identifier.issn | 1078-8956 | - |
dc.identifier.uri | http://hdl.handle.net/10203/299465 | - |
dc.description.abstract | An engineered fusion protein exploits the efferocytosis pathway to clear amyloid-beta (A beta) from the brain without eliciting the severe inflammatory adverse effects associated with A beta-targeting antibody-based immunotherapies. In mouse models of Alzheimer's disease, this approach induced robust clearance of A beta without inflammation, improved synapse protection, and decreased brain microhemorrhage, which result in superior behavioral recovery. | - |
dc.language | English | - |
dc.publisher | NATURE PORTFOLIO | - |
dc.title | Toward inflammation-free therapeutics in Alzheimer's disease | - |
dc.type | Article | - |
dc.identifier.wosid | 000851351400002 | - |
dc.identifier.scopusid | 2-s2.0-85138490147 | - |
dc.type.rims | ART | - |
dc.citation.volume | 28 | - |
dc.citation.issue | 9 | - |
dc.citation.beginningpage | 1765 | - |
dc.citation.endingpage | 1766 | - |
dc.citation.publicationname | NATURE MEDICINE | - |
dc.identifier.doi | 10.1038/s41591-022-01972-3 | - |
dc.contributor.localauthor | Kim, Chan Hyuk | - |
dc.contributor.localauthor | Chung, Won-Suk | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Editorial Material | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.